Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.

Gastroenterologia y Hepatologia, published by Elsevier España SLU, is a distinguished journal dedicated to advancing the fields of gastroenterology and hepatology. With a publication history spanning from 1982 to 2024, this journal is recognized for its commitment to disseminating high-quality research and reviews that address critical developments in the diagnosis and treatment of gastrointestinal and liver diseases. Although it currently ranks in the Q3 quartile in both gastroenterology and hepatology based on the 2023 metrics, the journal continues to attract a global audience of researchers, healthcare professionals, and students eager to engage with the latest findings. The journal is accessible in both print and electronic formats (ISSN: 0210-5705), making its valuable insights reachable to a broad spectrum of subscribers. By fostering a platform for rigorous scholarly communication, Gastroenterologia y Hepatologia plays a vital role in shaping the future of research in these essential medical fields.

Translational Gastroenterology and Hepatology, published by AME Publishing Company, stands as a pivotal platform for advancing the understanding and treatment of gastrointestinal and liver diseases. With its focus on translational research, this journal aims to bridge the gap between laboratory discoveries and clinical applications, thus fostering improvements in patient care. Although specific metrics like H-Index and Scopus ranks are currently unavailable, the journal is committed to maintaining high standards of scholarly communication and excellence. As an open-access publication, it ensures that valuable findings are readily accessible to a global audience, promoting collaboration and innovation among researchers, clinicians, and healthcare professionals invested in gastroenterology and hepatology. The journal's dedication to disseminating groundbreaking research makes it an essential resource for those seeking to stay at the forefront of these ever-evolving fields.

Hepatology International is a premier academic journal dedicated to advancing the field of liver research and hepatology. Published by SPRINGER, this journal boasts a prestigious Q1 ranking in Hepatology as of 2023, underscoring its commitment to high-quality research dissemination. The journal’s scope encompasses a wide range of topics related to liver disease, including clinical, translational, and basic science studies. With its impact factor reflecting its relevance and influence in the field, Hepatology International serves as an essential resource for researchers, clinicians, and students aiming to keep abreast of the latest developments and breakthroughs. Though traditionally a subscription-based journal, it offers a vast array of insightful articles that contribute significantly to our understanding of hepatological conditions. The journal continues its trajectory of growth since its inception in 2008, anticipating a convergence of knowledge and innovation through to 2024. Located in the heart of New York City, this journal not only represents a crucial platform for global hepatology research but also fosters a collaborative community of experts dedicated to improving liver health worldwide.

Liver Cancer is a premier, peer-reviewed journal dedicated to the comprehensive study and advancement of knowledge surrounding liver neoplasms. Published by KARGER and headquartered in Switzerland, this journal has been an open-access platform since 2012, providing researchers with invaluable insights into the rapidly evolving field of hepatology and oncology. With an impressive impact factor that places it in the Q1 category for both Hepatology and Oncology in 2023, Liver Cancer stands out as a high-impact conduit for groundbreaking research, ranking #19 out of 404 in Medicine _ Oncology and #6 out of 82 in Medicine _ Hepatology according to Scopus. Researchers, practitioners, and students are encouraged to engage with the journal's content, which encompasses clinical studies, basic research, and reviews that contribute significantly to understanding liver cancer dynamics, diagnosis, and treatment strategies. This journal not only facilitates the dissemination of knowledge but also fosters collaboration in a well-established and impactful global scientific community.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.

ZEITSCHRIFT FUR GASTROENTEROLOGIE, published by GEORG THIEME VERLAG KG, stands as a notable journal in the field of gastroenterology since its inception in 1971. With an ISSN of 0044-2771 and an E-ISSN of 1439-7803, this journal focuses on advancing knowledge and research in gastrointestinal health. Operating from Germany, its contributions span various aspects of gastroenterology, providing a platform for both established and emerging scholars to share their findings. As of 2023, ZEITSCHRIFT FUR GASTROENTEROLOGIE is ranked in the Q3 quartile in Gastroenterology and Q4 in Medicine (miscellaneous), reflecting its critical yet developing role in the academic community. Despite its current Scopus rank of #117 out of 167 in the gastroenterology category, the journal aims to foster innovative research and discussions vital for tackling contemporary challenges in gastrointestinal medicine. While it does not offer open access, the journal's extensive archival rigor ensures that pertinent studies remain accessible to professionals and academicians seeking to deepen their understanding and engage with evolving clinical practices.

SEMINARS IN LIVER DISEASE is a premier journal dedicated to advancing the field of hepatology, published by THIEME MEDICAL PUBL INC. Established in 1981, it has become a respected resource within the academic community, providing high-quality peer-reviewed articles that cover a broad range of topics related to liver diseases. With an impressive impact factor and recognized as a Q1 journal in the hepatology category, it ranks 17th out of 82 journals in the field, placing it in the top 21% of its category according to Scopus rankings. Although it does not offer open access, the journal’s rigorous standards and extensive network ensure that it reaches a wide audience of clinicians, researchers, and students, fostering knowledge and innovation in liver disease management. The journal's objectives focus on disseminating critical insights and promoting informed discussions that can pave the way for future research and clinical advancements in hepatology.

JHEP Reports, published by ELSEVIER, stands at the forefront of scholarly communication in the fields of Gastroenterology, Hepatology, Immunology and Allergy, and Internal Medicine. As an Open Access journal since 2019, it provides a platform for the dissemination of high-quality research findings, making vital information readily accessible to a global audience. With a commendable impact characterized by a Q1 category ranking across four medical disciplines in 2023, JHEP Reports demonstrates its significance and influence, reflected in its impressive Scopus ranks—#11 in Gastroenterology and #14 in Internal Medicine, amongst others. This esteemed journal not only plays a critical role in advancing knowledge but also fosters collaboration among researchers, practitioners, and students keen on exploring innovations and breakthroughs in health sciences. At RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS, JHEP Reports is committed to bridging the gap between research and application, ushering in a new era of informed and effective healthcare solutions.

Hepatobiliary & Pancreatic Diseases International, an esteemed journal published by Elsevier, stands as a vital resource within the field of gastroenterology and hepatology. Established in 2002, this journal has developed a significant reputation, currently ranked in the second quartile (Q2) in both categories as of 2023, showcasing its commitment to high-quality research and clinical studies. Based in Singapore, Hepatobiliary & Pancreatic Diseases International serves as an essential platform for researchers, clinicians, and healthcare professionals to share innovative findings, therapeutic approaches, and advancements in the understanding of hepatobiliary and pancreatic diseases. Although the journal does not currently offer Open Access, its rigorous peer-review process ensures that published articles maintain the highest scientific standards, fostering knowledge dissemination among the global research community. With a convergence period extending to 2024, this journal continues to play a pivotal role in enhancing the understanding and treatment of complex gastrointestinal conditions, making it a must-read for anyone engaged in this dynamic field.